| Name | Title | Contact Details |
|---|---|---|
Brian Hobbs |
Director of IT | Profile |
EHC Communicationsm Inc is a Dobbs Ferry, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hortense and Louis Rubin Dialysis Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Troy, NY. To find more information about Hortense and Louis Rubin Dialysis Center, please visit www.rubindialysis.org
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
The Company was founded in April 1997 by Robert Rosenbluth and Brian Cox and incorporated as MicroVention, Inc. in September.
Gurwin Jewish Nursing and Rehabilitation Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Gurwin Jewish Nursing and Rehabilitation Center is based in Commack, NY. You can find more information on Gurwin Jewish Nursing and Rehabilitation Center at www.gurwin.org